Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/9/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Elaine R. Mardis

Wrong Dr. Elaine R. Mardis?

Co-Director

Phone: (314) ***-****  HQ Phone
Genome Sequencing Center
4444 Forest Park Boulevard
St. Louis , Missouri 63108
United States

Company Description: Founded in 2000, Genome Québec is a private, not-for-profit organization that funds research projects in genomics and proteomics. The organization is managing 21...   more
Background

Employment History

  • Director of Technology Development
    Genome Sequencing Center
  • Co-Director of the Genome Center
    Washington University
  • Professor of Genetics and Molecular Microbiology
    Washington University
  • Geneticist
    Washington University
  • Professor of Genetics
    Washington University School of Medicine
  • Associate Professor of Genetics
    Washington University School of Medicine
  • Co-Director of the Genome Sequencing Center
    Washington University School of Medicine
  • Co-Director
    Washington University Genome Sequencing Center
  • Professor of Genetics and Molecular Microbiology and the Co-Director
    The Genome Institute at Washington University School of Medicine
  • Chair of Basic and Translational Sciences
    American College of Surgeons
  • Senior Research Scientist for Four Years
    BioRad

Board Memberships and Affiliations

Education

  • PhD
  • B.S. degree , zoology
    University of Oklahoma
  • Ph.D. , Chemistry and Biochemistry
  • BS , Zoology
    University of Oklahoma
178 Total References
Web References
derived material before the vaccine ...
www.dddmag.com, 9 April 2015 [cached]
derived material before the vaccine peptides are defined," co-author Elaine Mardis Ph.D., told BioscienceTechnology. Mardis is co-director of the Genome Institute of Washington University.
"We used conventional in vitro lab assays, called 'Elispot,' with an isolate from each patient, to refine the list of peptides we generated from the work above (genomics, comparison of binding affinity)," Mardis said.
...
"Our approach does consider heterogeneity by evaluating, using genomics, the common neoantigens present in several metastatic lesions," Mardis told BioscienceTechnology. "Therefore, we develop the most broadly tumor-reactive set of T-cells. What we hope is that, like many other types of immunotherapy, we can establish that patients will have lasting or 'durable' responses, and they may indeed need only a single course of treatment."
The durability of the response is not optimal right now. "The peak response occurred eight weeks after the last vaccine round, and one of the open questions about this approach is whether patients will continue to have a durable response," Mardis said. "It's simply too early to know [although] we do think we can potentially culture the activated T cells so that patients can have a "booster shot" if needed."
Mardis can "absolutely" imagine bolstering the vaccine with complimentary therapies. "We do anticipate a second trial that combines the precision vaccine with a checkpoint blockade therapy to evaluate whether this is a better 'tweak'," she said.
...
In response, Mardis noted that, "in Figure 1A of the manuscript, we demonstrate that by sampling from several different tumor isolates for two of the patients, we were able to identify shared tumor-unique neoantigens.
...
Additionally, Mardis said, the digital nature of massively parallel sequencing data "enables us to also select the neoantigen candidates that are present in the founder clone of the tumor.
...
But the bottom line, said Mardis, is that "Dr.
The opening keynote address by Dr. ...
uhnres.utoronto.ca, 1 Feb 2014 [cached]
The opening keynote address by Dr. Elaine R. Mardis provided a glimpse into the future of personalized medicine. As Director of Technology Development for the Genome Institute (Washington University), she established an integrated and cutting-edge sequencing platform that enabled her, along with collaborators and clinicians, to create customized treatment protocols for patients with unresponsive cancers.
Scientific Advisory Board - Ingenuity
www.ingenuity.com, 21 Dec 2014 [cached]
Elaine Mardis
...
Elaine R. Mardis, Ph.D. Professor of Genetics and Molecular Microbiology. Co-director, The Genome Institute at Washington University School of Medicine.
Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation, Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA.
In 1993, Dr. Mardis joined The Genome Institute at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome. She currently orchestrates the Center's efforts to explore massively parallel sequencing technologies and to transition them into production sequencing capabilities as well as new applications.
Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.
Dr. Mardis serves as an editorial board member of Molecular Cancer Research, Genome Research and Molecular Oncology, and acts as a reviewer for Nature, the New England Journal of Medicine, Cell and Genome Research. She serves on the scientific advisory boards of Pacific Biosciences, Inc., DNA Nexus, and ZS Genetics. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and was named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011. She is the former chair of Basic and Translational Sciences for the American College of Surgeons Oncology Group (ACOSOG).
ZS Genetics Management Team
www.zsgenetics.com, 24 Oct 2014 [cached]
Elaine R. Mardis, PhD (SAB Chair) Dr. Elaine Mardis graduated Phi Beta Kappa from the University of Oklahoma with a B.S. degree in zoology. She then completed her Ph.D. in Chemistry and Biochemistry in 1989, also at Oklahoma. Following graduation, Dr. Mardis was a senior research scientist for four years at BioRad Laboratories in Hercules, CA.
In 1993, Dr. Mardis joined The Genome Institute at Washington University School of Medicine. As Director of Technology Development, she helped create methods and automation pipelines for sequencing the Human Genome. She currently orchestrates the Center's efforts to explore massively parallel sequencing technologies and to transition them into production sequencing capabilities as well as new applications.
Dr. Mardis has research interests in the application of DNA sequencing to characterize cancer genomes and transcriptomes, and using these data to support therapeutic decision-making. She also is interested in facilitating the translation of basic science discoveries about human disease into the clinical setting.
Dr. Mardis serves as an editorial board member of Molecular Cancer Research, Genome Research and Molecular Oncology, and acts as a reviewer for Nature, the New England Journal of Medicine, Cell and Genome Research. She serves on the scientific advisory boards of Qiagen Ingenuity, DNA Nexus, and ZS Genetics. Dr. Mardis received the Scripps Translational Research award for her work on cancer genomics in 2010, and was named a Distinguished Alumni of the University of Oklahoma College of Arts and Sciences for 2011. She is the former chair of Basic and Translational Sciences for the American College of Surgeons Oncology Group (ACOSOG).
Further information is available on Dr. Mardis at genome.wustl.edu/people/individual/elaine-mardis/.
Cancer : GlobalTort
www.globaltort.com, 31 May 2013 [cached]
Those costs have now fallen to below $100,000 for a tumor-normal combination, and the sequencing can be done in about a week, Dr. Wilson said. (See "A Conversation with Dr. Elaine Mardis 8" in this issue.)
...
The infrastructure and resources required for follow-up studies of the genomic data, such as mouse models, already exist at St. Jude, noted Dr. Elaine Mardis, co-director of the Genome Center at Washington University.
Other People with the name "Mardis":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304